Conference abstract · 2019
Conference abstractPublished 18 Jul 2019
Challenges in developing biosimilars
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Biopharmaceuticals are the new growth driver of the pharma industry. They are usually more difficult to develop via R&D, more expensive to produce and more challenging to navigate for regulatory approval and commercialize. The key challenges are finding the right talent, technology and investors who believe in the long-term vision of this field. The technology for biotechnology and biosimilar keeps changing and so do the regulations. It has often been the case when the company starts with technology X to develop products for the local market and some exports. Thereafter, the strategy changes to work on different markets. What are the implications of such changes? What role does government regulatory or policy place in biosimilars development? How does the regulatory strategy impact the effectiveness to develop the right products in a high quality and yet cost-effective manner? This requires huge upfront investment which can be challenging for small and mid-size companies to commit. Sometimes with small commitments, there are unrealistic expectations in terms of R&D or product quality. How much money does a company need for its biopharma strategy? Finding the right talent is difficult in emerging markets since the talent concentration is very high in developed markets and the ecosystem is well developed. Few emerging markets are breaking this barrier.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 19 Oct 2016
Operational and technical challenges for drug development, scale up, scale down and higher scale manufacturing of biosimilars
Conference abstract · 26 Oct 2015
Bioanalytical Challenges of Biosimilar Development; Making You Wish You Had a Mirror to Put In Front of the Innovator Drug
Conference abstract · 25 Sep 2014
Production of biosimilars in developing countries: Challenges and opportunities: SEDICO case Study
Conference abstract
Challenges in development of biologics and biosimilars: An overview
More from this journal
The newest in Pharmaceutica Analytica Acta.
Article · 16 Sep 2026
The Fc Domains in the Monoclonal Antibody and Fusion Protein Significantly Boost the Biocomposite Suspension's Power to Combat Harmful Microorganisms, Enhance Drug Delivery, and Improve Protein Stability
Article · 26 Jun 2026
Green Pathways in Drug Quality Assessment: The Growing Role of Sustainable Pharmaceutical Analytics
Article · 26 Jun 2026
Advanced Single-Cell Signal Analysis: The Role of Ghost Cytometry in Cell Therapy Characterization
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutica Analytica Acta
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Subir K Basak”

